Author of

• 20177

  +

  P2.13 - Radiology/Staging/Screening (ID 714)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Radiology/Staging/Screening
  • Presentations: 2
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23474

    +

    P2.13-005 - Early Results of Lung Cancer Screening in an African American Population (ID 9020)

    09:30 - 09:30  |  Author(s): R.F. Moore
    • Abstract

    Background:
    African Americans have been underrepresented in trials showing survival benefit to lung cancer screening. We implemented a multidisciplinary lung cancer screening program in an African American population. We hypothesize that lung cancer screening in an African American population will lead to safe detection and treatment of lung cancer.
    
    Method:
    In an urban, academic medical center, we prospectively gathered information on African American patients referred to a multidisciplinary lung cancer screening program from October 2015 to December 2017 with a 6 month follow up. We studied, age, gender, smoking history and level of education. We measured lung cancer screening results using Lung-RADs categorizations, diagnosis of cancer, treatment modality and complications.
    
    Result:
    Of 160 African Americans undergoing lung cancer screening, the average age was 64.2 (SD 5.75), 95 (59.3%) were women, 111 (69.3%) were current smokers, average pack years was 47.2 (SD 17.1) and level of education was less than high school in 52 (32.5%), high school in 53 (33.1%), advanced education in 45 (28.1%) and 10 (6.2%) declined to report. LDCT results were 1 (0.6%) with Lung-RADs 0; 69 (43.1%) with Lung-RADs 1; 73 (45.6%) Lung-RADs 2; 7 (4.3%) Lung-RADs 3; 10 (6.3%). Of the 6 people undergoing invasive procedure for biopsy (3 CT guided needle biopsy, 1 transbronchial needle biopsy, 2 surgical resection) 4 were diagnosed with stage I non-small cell lung cancer. Three of these underwent surgical resection for treatment, and one underwent radiation treatment.

    Lung Cancer Screening in an African American Population

    	Number	Percent
    Total	160	100%
    Average Age	64.2
    Average Pack Years	47.2
    Active Smokers	111	69.4%
    Former Smokers	49	30.6%
    Gender
    Women	95	59.4%
    Men	65	40.6%
    Education
    Less Than High School	52	32.5%
    High School	53	33.1%
    Advanced Education	45	28.1%
    Declined to Answer	19	6.3%
    Lung-RADs Category
    Lung-RADs 0	1	0.6%
    Lung-RADs 1	69	43.1%
    Lung-RADs 2	73	45.6%
    Lung-RADs 3	7	4.4%	1 diagnosed with stage I lung cancer with CT guided biopsy
    Lung-RADs 4	10	6.3%	3 diagnosed with stage I lung cancer, 1 with CT guided biopsy, 2 with surgical biopsy
    Total Receiving Biopsy	6	3.8%
    CT Guided	3	1.9%	2 diagnosed with stage I lung cancer
    Transbronchial	1	0.6%
    Surgical Resection	2	1.3%	2 diagnosed with stage I lung cancer
    Lung Cancer Diagnosis	4	2.5%
    Stage I	4	2.5%
    Stage II	0	0%
    Stage III	0	0%
    Stage IV	0	0%
    Adenocarcinoma	4	2.5%
    Squamous Cell	0	0%
    Treatment
    Surgical Resection	2	1.3%
    Radiation	1	0.6%
    Complications	0	0%

    
    
    Conclusion:
    Implementation of a multidisciplinary lung cancer screening program enrolling African Americans at high risk of lung cancer led to detection and treatment of lung cancer in 2.5%. Only 10.7% had positive screens (lung-RADs 3 or 4), 3.8% had an invasive biopsy and no one had complications from diagnostic procedures or treatment. Further study is necessary to understand long-term survival benefit of lung cancer screening.
    
    

  • 23475

    +

    P2.13-006 - Enhanced Shared Decision Making in Lung Cancer Screening: Addressing Questions of Willingness and Ability to Undergo Lung Cancer Treatment (ID 9070)

    09:30 - 09:30  |  Author(s): R.F. Moore
    • Abstract

    Background:
    Lung Cancer Screening with low dose CT (LDCT) can reduce lung cancer death, but only if those found to have lung cancer proceed with lung cancer treatment. When implemented into diverse populations, lung cancer screening may prove less effective if patients are unwilling or unable to undergo lung cancer treatment. We employed an enhanced shared decision making (SDM) model to address willingness and ability to undergo lung cancer treatment before low dose CT (LDCT) scanning. We hypothesized that enhanced SDM was feasible and did not discourage patients or providers from proceeding with lung cancer screening.
    
    Method:
    We performed a prospective study of patients referred for lung cancer screening between October of 2015 and May of 2017. We measured race, gender, adherence to the consent process and questions regarding willingness and ability to undergo lung cancer treatment. Subsequent uptake of LDCT, outcomes of cancer diagnosis and failure to follow up were also studied.
    
    Result:
    Of 363 enrolled study participants, 59% were African American, 12% were Caucasian, 12% were Hispanic and 2% were Asian. The gender distribution was 186 male (51.2%) and 177 female (48.8%). All 363 patients had a documented SDM visit addressing the risks and benefits of lung cancer screening and consented to discuss lung cancer treatment if lung cancer is diagnosed. When asked if they were willing to undergo lung cancer treatment, 15 (4.1%) people responded “no”, 4 (1.1%) people responded “unknown” and 8 (2.2%) did not have a documented answer. When asked if they were able to undergo lung cancer treatment 10 (2.8%) people responded “no”, 2 (0.5%) people responded “unknown” and 8 (2.2%) people did not have a documented answer. Overall, 6 (1.7%) people were diagnosed and treated for lung cancer. Only 1 person declined screening despite being willing and able to undergo lung cancer treatment. One (0.2%) person failed to follow up on a suspicious nodule found on lung cancer screening despite reporting being willing and able to undergo lung cancer treatment.
    
    Conclusion:
    Though SDM is essential to lung cancer screening, there are few guidelines on how to conduct this process. This study demonstrated that an enhanced SDM experience, including questions about willingness and ability to undergo lung cancer treatment, is a feasible practice that did not deter patients or providers from proceeding with lung cancer screening. Our enhanced SDM experience gave clinicians and patients a framework to emphasize the importance of appropriate follow up of positive screens.